Our population-based study provided evidence for the potential CV benefits of treatment with the GLP-1R agonist exenatide, while used in combination with conventional anti-diabetic therapies in reducing risks of HF, MI and stroke in patients with T2DM. Here, GLP1R is linked to Stroke.